The authors searched and synthesized the literature to identify current recommendations for early detection of ovarian cancer, the female reproductive cancer with the highest mortality rate. After providing background information regarding risk factors for ovarian cancer and discussing the challenges of detecting this disease at an early stage, the authors list the most recent clinical guidelines from a variety of sources.
Women's Healthcare www.NPWOMENSHEALTHCARE.com A mong all female repro ductive cancers, ovarian cancer has the highest mortality rate. 13 Although the incidence of ovarian cancer is relatively low, overall survival is only 35%. 1 In 2013, 22,240 new cases of ovarian cancer were diagnosed and 14,030 women died of the disease, 4 making it the fifth leading cause of cancer death in females, behind lung, breast, colon and pancreatic can cers. 5 Whereas earlier stage at di agnosis has been linked to an in creased survival rate (70%90%), ovarian cancer is commonly found at more advanced stages, resulting in a 5year survival rate of only 15%. 2, 69 Mortality reduc tion may be possible with earlier detection. 10 The purpose of this article is to synthesize the literature and iden tify current recommendations re garding early detection of ovarian cancer. The authors searched the PubMed and CINAHL databases for primary, peerreviewed stud ies reported between 2005 and 2013. This reviewandsynthesis is based on 47 articles and 11 rele vant clinical guidelines identified in the search.
Risk factors
Although no evidencebased ovarian cancer screening recom mendations exist for women in the general population, 11 study findings indicate that women at higher risk for ovarian cancer need to be evaluated differently. Three areas of increased risk are age, personal history, and genetics.
Age-Age is the single most important risk factor for ovarian cancer. The incidence increases significantly after menopause (average age at diagnosis, 63 years). 12 Personal history-Some breast cancer survivors are at an increased risk for ovarian cancer; the risk is 12.7% in those with the breast cancer susceptibility gene 1 (BRCA1) mutation and 6.8% for those with the breast cancer sus ceptibility gene 2 (BRCA2) muta tion. 13 Ovarian cancer risk after breast cancer is also higher in women with a positive family his tory of breast cancer. 5 Breast cancerfree women with a family history of breast or ovarian can cer but without the BRCA1/2 mutation have a risk closer to that in the general popula tion. 14, 15 Women diagnosed with hereditary nonpolyposis colorec tal cancer, also known as Lynch syndrome, have a 10%36% risk of developing ovarian cancer. 16 Other factors increasing ovarian cancer risk include endometrio sis, nulliparity, infertility, early menarche, late menopause, and living in a Western industrialized nation. 13 In addition, ovarian can cer has been associated with obesity, failure to follow a lowfat diet, use of fertility drugs or an drogens, and use of unopposed estrogens after menopause, al though no studies have proved causation in these cases. 5 Genetic risk and assessment-Approximately 10% of ovarian cancer cases are related to mutation of the BRCA1/2 gene, which can be inherited. 13 In the general population, the risk of having either mutation is 1:300 to 1:800. 13 Women of Ashkenazi Jewish descent have a 10fold higher risk of having either mutation. 13 If a woman has a BRCA1/2 mutation, her lifetime risk of developing ovari an cancer is 65%74%, placing her in a highrisk category. 13 The term hereditary breast and ovarian cancer syndrome (HBOCS) is used to describe the tendency to develop breast and/or ovarian cancer because of an inherited BRCA1/2 gene mutation. The American Con gress of Obstetricians and Gy necologists (ACOG) has issued specific referral guidelines for women with HBOCS. 13 The National Cancer Center Network and the Society of Gy necological Oncology (SGO) rec ommend that women at risk for reproductive cancerrelated ge netic mutations be referred for formal genetic counseling. 17, 18 Despite this advice, Levy et al 19 have reported that few primary care practitioners (PCPs) follow these referral guidelines.
Challenges of early ovarian cancer detection
Early ovarian cancer detection is challenging because symptoms are often vague, leading to mis diagnosis. 20 Screening is not rec ommended for the general pop ulation because of the lack of effective screening methods in this population. 11 Despite the availability of triage and referral guidelines, many women's com plaints are not fully investigated or appropriately referred by the PCP. 19, 21, 22 Symptoms-More than two thirds of all ovarian cancers are diagnosed at a later stage (III or IV), when the disease has already spread to other intraabdominal organs. 7, 8 Factors contributing to late diagnosis include vague symptoms and lack of a defini tive precursor lesion. 8 Many women report symptoms to their PCP a few months before diagnosis, 2 yet they are misdiag nosed 70%75% of the time. 20 Contrary to previous thought, ovarian cancer can present with symptoms. 7 In fact, gastrointesti nal, urinary, or gynecologic symptoms are common; com plaints often include abdominal bloating, a pelvic mass, pain, or malaise. 3, 7, 9, 23 Usefulness of the presence of symptoms as a trigger for early screening has been evaluated. Goff et al 1 developed a symp tom index based on the pres ence of pelvic/abdominal pain, an increase in abdominal size, bloating, and difficulty eating or early satiety. In terms of identi fying early ovarian cancer, the Goff symptom index was found to have a sensitivity of 56.7%, as well as a specificity of 90% for women older than 50 years and of 86.7% for women younger than 50 years. Al though several symptom index es are being studied, evidence 24, 25 certain challenges exist. These screen ing methods must also have high sensitivity, specificity, and positive predictive value (PPV). 25 With regard to ovarian cancer, screening tests need to have a sensitivity of ≥75% and a specificity of >99.6% to yield a PPV of ≥10%. 24, 26 (The specifici ty requirement is high because of the low prevalence of ovarian cancer in the general popula tion.) Effective screening would result in 10 exploratory surger ies for every detected cancer case, which is the minimum ac cepted screening requirement determined by statistical esti mates. 24, 26 The low specificity, sensitivi ty, and PPV of bimanual pelvic examination, imaging, and tu mor markers, used independ ently in the general population, lead to the possibility of unnec essary exploratory surgery and/or patient stress, 27 posing the risk that harm will outweigh benefits. 11 The United States Preventive Services Task Force (USPSTF) recently reviewed the evidence for ovarian cancer screening and did not recom mend screening for women at average risk. 11 However, women with increased risk related to BRCA 1/2 mutations, Lynch syn drome, or a family history of ovarian cancer should be con sidered for genetic counseling to further evaluate their risk. 11 Triage techniques-Several studies have suggested im proved survival if women with possible ovarian cancer are managed by a gynecologic on cologist. 28 ACOG and the SGO have issued referral guidelines: Women of all ages with ascites, evidence of metastasis, or a firstdegree relative with breast or ovarian cancer should be re ferred to a gynecologic oncolo gist. 12,29 Premenopausal women should be referred only if they have a CA125 level >200 U/mL, whereas postmenopausal women should be referred if they have any elevation in CA125 or a nodular or fixed pelvic mass. 12, 29 Delay in diagnosis is a prob lem in ovarian cancer. One study showed that the median interval from first symptom to diagnosis was 74.5 days. 21 In addition, PCPs were not consistent in terms of the specialist to whom they referred patients; among the 92% of patients who were re ferred, only 31% were referred to a gynecologist. 21 One study showed that as a woman's age increases, the likelihood that her complaint was investigated or that she was referred decreased, contributing further to a delay in diagnosis. 22 
Discussion
Studies examining the effective ness of various screening strate gies, alone or combined with each other, are ongoing, and 24, 25 • The condition should be an important health problem for both the individual and the community, with either a high prevalence or serious consequences.
• There should be an adequate treatment for patients with the recognized condition. In addition, early treatment should improve prognosis.
• Diagnostic and treatment facilities should be available for the condition.
• There should be a latent or early symptomatic stage that is recognizable by the patient or physician.
• There should be a test or method of examination that is suitable for screening or diagnosis. Methods of screening should have high positive predictive value, sensitivity, and specificity.
• The test should be easy and acceptable enough so that, in general, patients will consent to participating.
• The natural history of the condition should be adequately understood.
• A policy of whom to treat should be agreed upon.
• The cost of screening, diagnosis, and treatment should be economically balanced in relation to the overall health of the population and economy.
• Screening should be a continuous process. 
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• Risk assessment is recommended for women with a 20%-25% risk for inherited Oncologists breast and ovarian cancer. These women include those with a personal history of both breast and ovarian cancer; those with ovarian cancer and a close relative with ovarian cancer, premenopausal breast cancer, or both; Ashkenazi Jewish women with ovarian cancer or breast cancer at age 40 years or younger; those aged 50 years or younger and a close relative with ovarian cancer or male breast cancer; and those with a close relative having a BRCA1/2 mutation. • Risk assessment may be helpful for women with a 5%-10% risk for inherited breast and ovarian cancer. These women include those with breast cancer at age 40 years or younger; those with ovarian cancer, primary peritoneal cancer, or fallopian tube cancer of high grade, serous histology at any age; those with bilateral breast cancer (especially if diagnosed at age ≤50 years), those with breast cancer at age 50 years or younger and a close relative with breast cancer at age 50 years or younger; those with breast cancer at any age and two or more close relatives* with breast cancer at any age (especially if at least one case of breast cancer was diagnosed at age 50 years or younger); and unaffected women with close relatives meeting the criteria above. Triage: Transvaginal USG is the imaging modality of choice for a pelvic mass. Simple cysts up to 10 cm in diameter are almost always benign, even in postmenopausal patients.
• Premenopausal women: Refer premenopausal women to a gynecologic oncologist when there is an elevation of CA-125 >200 U/mL, ascites, evidence of metastasis by exam or imaging, or family history of breast or ovarian cancer in a first-degree relative.
• Postmenopausal women: Any CA-125 elevation in a postmenopausal woman has a high suspicion for malignancy. Therefore, refer postmenopausal women to a gynecologic oncologist if these women have elevated CA-125 levels, ascites, nodular or fixed pelvic mass, evidence of metastasis by exam or imaging, or family history of breast or ovarian cancer in a first-degree relative.
(continued on next page)
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Organization Recommendations
Agency for Healthcare Research and Quality Genetics: Further research needs to be performed using appropriately designed studies before genetic testing can be recommended because the clinical utility of changing management based on tests has not been thoroughly evaluated. There is promising research, but the studies have been biased or limited.
American Medical Association
Genetics: Early screening for breast and ovarian cancer could benefit women with BRCA1 mutations. Early screening for breast cancer could benefit women with BRCA2 mutations.
National Comprehensive Cancer Network
Symptomatic women: Women with a palpable pelvic mass having symptoms of ascites, abdominal distention, bloating, pelvic or abdominal pain, difficulty eating or feeling full quickly, or urinary urgency or frequency, without another source of malignancy, should have an abdominopelvic exam, USG and/or abdominal/pelvic CT, chest imaging, complete blood cell count, and liver function tests. A CA-125 or other tumor marker measurement, gastrointestinal evaluation, or evaluation of family history should be considered. Genetics: Criteria for further risk evaluation by a genetics specialist include at least one of the following:
In an affected individual: (a) known breast cancer genetic mutation in the family, (b) breast cancer before age 50, (c) triple negative breast cancer, (d) two breast cancer primaries in the individual, (e) breast cancer and one or more close relatives with early breast cancer, epithelial ovarian cancer, or two close relatives with breast cancer and/or pancreatic cancer at any age, or from an increased-risk population, (f) at least one family member with breast cancer and pancreatic cancer, aggressive prostate cancer, sarcoma, adrenocortical carcinoma, brain tumors, endometrial cancer, leukemia/lymphoma, thyroid cancer, dermatologic manifestations and/or macrocephaly, hamartomatous polyps of GI tract, diffuse gastric cancer, (g) ovarian cancer, (h) male breast cancer In an unaffected individual: a family history of one or more of the following: (a) known breast cancer genetic mutation in the family, (b) at least two breast primaries in a single individual, (c) at least 2 individuals with breast primaries on the same side of the family, (d) at least one ovarian cancer primary from the same side of the family, (e) first-or second-degree relative with breast cancer at age 45 years or younger, (f) at least one family member on the same side of the family with a combination of breast cancer and at least one of the following: pancreatic cancer, aggressive prostate cancer, sarcoma, adrenocortical carcinoma, brain tumors, endometrial cancer, leukemia/lymphoma, thyroid cancer, dermatologic manifestations and/or macrocephaly, hamartomatous polyps of GI tract, diffuse gastric cancer, (g) male breast cancer
Society of Gynecologic Oncologists
Genetics: Women at risk for hereditary breast and ovarian cancer syndromes should be identified, assessed, and counseled about obtaining genetic tests. Serum biomarkers: Tumor marker panels have not been adequately evaluated and
have not yet proved to improve early detection of ovarian cancer.
United States Preventive Services Task Force
Genetics: The low population prevalence of ovarian cancer would produce a low yield from routine screening, but women at high familial risk may benefit from screening. Routine screening: Routine screening for ovarian cancer is not recommended. There is fair evidence for early detection using CA-125 or transvaginal USG, but it would have very little effect on mortality. The harms of diagnostic procedures outweigh the benefits of screening (grade D recommendation).
*A close relative is defined as a first-, second-, or third-degree relative. CT, computed tomography; FDG-PET; fluorodeoxyglucose positron emission tomography; GI, gastrointestinal; MRI, magnetic resonance imaging; USG, ultrasonography; USPSTF, United States Preventive Services Task Force. to yield a PPV of ≥10%). 24, 26 Although many detection meth ods meet some of these criteria, few fulfill all requirements for nonhighrisk women. There fore, this review supports the USPSTF conclusion that suffi cient evidence is lacking to recommend ovarian cancer screening for the general popu lation. 11 Existing guidelines are outlined in Table 2 . Despite the USPSTF conclu sion, certain specific situations place women in highrisk cate gories that may still benefit from early detection measures. 13, 30 Nurse practitioners should be aware of what constitutes higher risk for ovarian cancer (e.g., cer tain genetic mutations, family history). If a woman has familial and other risk factors, NPs should offer her the option of genetic counseling. 18 Current imaging standards support the use of transvaginal ultrasonogra phy for initial evaluation of ovar ian masses. 12 Other modalities, such as computed tomography and magnetic resonance imag ing, are used by specialists to evaluate an ovarian mass pre operatively. NPs should know that an elevation of CA125 has more clinical significance in postmenopausal women than in premenopausal women. 
Conclusion
